WO2022222965A1 - Dérivé de pyridine et son utilisation en médecine - Google Patents

Dérivé de pyridine et son utilisation en médecine Download PDF

Info

Publication number
WO2022222965A1
WO2022222965A1 PCT/CN2022/087968 CN2022087968W WO2022222965A1 WO 2022222965 A1 WO2022222965 A1 WO 2022222965A1 CN 2022087968 W CN2022087968 W CN 2022087968W WO 2022222965 A1 WO2022222965 A1 WO 2022222965A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
membered
heterocycloalkyl
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2022/087968
Other languages
English (en)
Chinese (zh)
Inventor
张靖
魏用刚
周锡兵
高成
孙毅
Original Assignee
成都百裕制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 成都百裕制药股份有限公司 filed Critical 成都百裕制药股份有限公司
Priority to CN202280015678.XA priority Critical patent/CN116867784A/zh
Publication of WO2022222965A1 publication Critical patent/WO2022222965A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne un composé de formule (I) de la présente invention et son utilisation en médecine. Ledit composé peut être utilisé pour traiter des tumeurs.
PCT/CN2022/087968 2021-04-23 2022-04-20 Dérivé de pyridine et son utilisation en médecine WO2022222965A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280015678.XA CN116867784A (zh) 2021-04-23 2022-04-20 吡啶衍生物及其在医药上的应用

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN202110440527.6 2021-04-23
CN202110440527 2021-04-23
CN202111374283 2021-11-19
CN202111374283.2 2021-11-29
CN202111543677.6 2021-12-17
CN202111543677 2021-12-17
CN202210034040.2 2022-01-04
CN202210034040 2022-01-14
CN202210120993.0 2022-02-10
CN202210120993 2022-02-10

Publications (1)

Publication Number Publication Date
WO2022222965A1 true WO2022222965A1 (fr) 2022-10-27

Family

ID=83667865

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2022/087966 WO2022222964A1 (fr) 2021-04-23 2022-04-20 Dérivé de pyridine et son utilisation en médecine
PCT/CN2022/087968 WO2022222965A1 (fr) 2021-04-23 2022-04-20 Dérivé de pyridine et son utilisation en médecine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/087966 WO2022222964A1 (fr) 2021-04-23 2022-04-20 Dérivé de pyridine et son utilisation en médecine

Country Status (3)

Country Link
CN (3) CN116867783A (fr)
TW (2) TWI827016B (fr)
WO (2) WO2022222964A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
US11795173B1 (en) 2022-04-28 2023-10-24 Xinthera, Inc. Substituted pyridines as PARP1 inhibitors
US11802128B2 (en) 2021-10-01 2023-10-31 Xinthera, Inc. Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023046158A1 (fr) * 2021-09-26 2023-03-30 张文燕 Composé d'azaquinolinone et son utilisation médicale
WO2024067691A1 (fr) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 Composé hétérocyclique contenant de l'azote et son utilisation pharmaceutique
CN117946074A (zh) * 2022-10-20 2024-04-30 上海海和药物研究开发股份有限公司 具有parp1抑制活性的化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960975A (zh) * 2004-03-30 2007-05-09 安万特药物公司 作为多聚(adp－核糖)聚合酶(parp)抑制剂的取代的吡啶酮
CN107922409A (zh) * 2015-08-17 2018-04-17 鲁宾有限公司 作为parp抑制剂的杂芳基衍生物
WO2021013735A1 (fr) * 2019-07-19 2021-01-28 Astrazeneca Ab Inhibiteurs de parp1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2215075T3 (pl) * 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
CN102952118B (zh) * 2011-08-17 2016-03-23 上海迪诺医药科技有限公司 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
CN115677688A (zh) * 2021-07-23 2023-02-03 南京明德新药研发有限公司 1,5-萘啶酮类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960975A (zh) * 2004-03-30 2007-05-09 安万特药物公司 作为多聚(adp－核糖)聚合酶(parp)抑制剂的取代的吡啶酮
CN107922409A (zh) * 2015-08-17 2018-04-17 鲁宾有限公司 作为parp抑制剂的杂芳基衍生物
WO2021013735A1 (fr) * 2019-07-19 2021-01-28 Astrazeneca Ab Inhibiteurs de parp1

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
US11802128B2 (en) 2021-10-01 2023-10-31 Xinthera, Inc. Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
US11795173B1 (en) 2022-04-28 2023-10-24 Xinthera, Inc. Substituted pyridines as PARP1 inhibitors

Also Published As

Publication number Publication date
TWI827016B (zh) 2023-12-21
CN115232121B (zh) 2023-08-29
TW202300149A (zh) 2023-01-01
CN116867783A (zh) 2023-10-10
WO2022222964A1 (fr) 2022-10-27
TWI827017B (zh) 2023-12-21
TW202241894A (zh) 2022-11-01
CN115232121A (zh) 2022-10-25
CN116867784A (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
WO2022222965A1 (fr) Dérivé de pyridine et son utilisation en médecine
AU2011288876B2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
WO2018118842A1 (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
JP2016512239A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
BRPI0708615A2 (pt) compostos de pirazol heterobicìclicos e métodos de uso
BR112013025732B1 (pt) Compostos de imizazo-oxazina, seus usos e composição farmacêutica e fármaco compreendendo os mesmos
TW201004935A (en) Substituted triazinone derivatives
WO2022222966A1 (fr) Inhibiteur sélectif de parp1 et son application
AU2018223982B2 (en) 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
US11147801B2 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
TW200936140A (en) Substituted arylamide oxazepinopyrimidone derivatives
WO2023088408A1 (fr) Inhibiteur sélectif de parp1 et son application
JP2016540773A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
WO2021041976A1 (fr) Composés indolinyle inhibiteurs de perk
KR20230012020A (ko) 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도
EP4223759A1 (fr) Composé pyrazolopyridazinone, composition pharmaceutique le contenant et son utilisation
EP3615027B1 (fr) Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
CN114478537B (zh) 环酰胺并环化合物及其医药用途
WO2022143533A1 (fr) Dérivé de quinazoline et son utilisation en médecine
KR20230012041A (ko) 3,4-디하이드로이소퀴놀린계 화합물 및 그 사용
TWI548637B (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
WO2022152313A1 (fr) Dérivé de pyrimidine et son application pharmaceutique
CN117126140A (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
CN116693501A (zh) 一种喹唑啉酮衍生物及其在医药上的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22791071

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280015678.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22791071

Country of ref document: EP

Kind code of ref document: A1